Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrocodone Bitartrate

FDA-approved product (capsule, extended release, oral), marketed as Hydrocodone Bitartrate, Hysingla Er, Vantrela Er and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Hydrocodone Bitartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cough
  • Drug dependence
  • Pain

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural opium alkaloids; Opium alkaloids and derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrocodone Bitartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrocodone Bitartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients

    NCT00583869 · start 2007-05

    Registered record
    Registry ID
    NCT00583869
    Conditions
    Post-operative Pain
    Interventions
    Placebo; Pregabalin; Pregabalin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2007-05
    Completion
    2009-08
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-operative Pain
    InterventionPlacebo; Pregabalin; Pregabalin
    PhaseEarly phase 1
    Registry statusCompleted

  • Trial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions

    NCT01011634 · start 2007-05

    Registered record
    Registry ID
    NCT01011634
    Conditions
    Undesired Intrauterine Pregnancy; First Trimester Pregnancy
    Interventions
    Intravenous moderate sedation versus oral medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-05
    Completion
    2008-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUndesired Intrauterine Pregnancy; First Trimester Pregnancy
    InterventionIntravenous moderate sedation versus oral medication
    PhasePhase 4
    Registry statusTerminated

  • A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine

    NCT00314340 · start 2005-11

    Registered record
    Registry ID
    NCT00314340
    Conditions
    Chronic Pain
    Interventions
    Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-11
    Completion
    2008-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Pain
    InterventionMarkers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery

    NCT00404391 · start 2003-10

    Registered record
    Registry ID
    NCT00404391
    Conditions
    Pain
    Interventions
    Hydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2003-10
    Completion
    2004-03
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionHydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

    NCT02197156 · start 2002-08

    Registered record
    Registry ID
    NCT02197156
    Conditions
    Postoperative Pain
    Interventions
    10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER; 10 mg HC / 325 mg APAP; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-08
    Completion
    2003-02
    Enrolment
    241

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    Intervention10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER +2 more
    PhasePhase 2
    Registry statusCompleted